Exact Sciences Corporation (EXAS)

$42.75

+0.61

(+1.45%)

Market is closed - opens 7 PM, 14 Jun 2024

Insights on Exact Sciences Corporation

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 646.88M → 637.52M (in $), with an average decrease of 1.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 794.0K → -110.22M (in $), with an average decrease of 3244.6% per quarter

  • Vs TMO

    In the last 1 year, Thermo Fisher Scientific, Inc. has given 10.1% return, outperforming this stock by 64.2%

  • Vs TMO

    In the last 3 years, Thermo Fisher Scientific, Inc. has given 21.8% return, outperforming this stock by 87.6%

Performance

  • $41.61
    $42.95
    $42.75
    downward going graph

    2.67%

    Downside

    Day's Volatility :3.12%

    Upside

    0.47%

    downward going graph
  • $41.60
    $100.77
    $42.75
    downward going graph

    2.69%

    Downside

    52 Weeks Volatility :58.72%

    Upside

    57.58%

    downward going graph

Returns

PeriodExact Sciences CorporationSector (Health Care)Index (Russel 2000)
3 Months
-26.96%
0.0%
0.0%
6 Months
-36.95%
7.8%
0.0%
1 Year
-54.06%
12.1%
0.0%
3 Years
-65.8%
17.1%
-24.0%

Highlights

Market Capitalization
7.9B
Book Value
$17.04
Earnings Per Share (EPS)
-1.31
PEG Ratio
-1.07
Wall Street Target Price
85.21
Profit Margin
-9.48%
Operating Margin TTM
-15.12%
Return On Assets TTM
-3.15%
Return On Equity TTM
-7.76%
Revenue TTM
2.5B
Revenue Per Share TTM
14.0
Quarterly Revenue Growth YOY
5.800000000000001%
Gross Profit TTM
1.5B
EBITDA
-108.4M
Diluted Eps TTM
-1.31
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.13
EPS Estimate Next Year
-0.15
EPS Estimate Current Quarter
-0.47
EPS Estimate Next Quarter
-0.23

Analyst Recommendation

Buy
    89%Buy
    10%Hold
    0
    0%Sell
Based on 29 Wall street analysts offering stock ratings for Exact Sciences Corporation(by analysts ranked 0 to 5 stars)
Based on 29 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
26
26
26
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 99.32%

Current $42.75
Target $85.21

Company Financials

FY18Y/Y Change
Revenue
454.5M
↑ 70.86%
Net Income
-175.1M
↑ 53.11%
Net Profit Margin
-38.54%
↑ 4.47%
FY19Y/Y Change
Revenue
876.3M
↑ 92.82%
Net Income
-84.0M
↓ 52.04%
Net Profit Margin
-9.59%
↑ 28.95%
FY20Y/Y Change
Revenue
1.5B
↑ 70.19%
Net Income
-848.5M
↑ 910.24%
Net Profit Margin
-56.9%
↓ 47.31%
FY21Y/Y Change
Revenue
1.8B
↑ 18.49%
Net Income
-595.6M
↓ 29.81%
Net Profit Margin
-33.71%
↑ 23.19%
FY22Y/Y Change
Revenue
2.1B
↑ 17.95%
Net Income
-623.5M
↑ 4.68%
Net Profit Margin
-29.91%
↑ 3.8%
FY23Y/Y Change
Revenue
2.5B
↑ 19.93%
Net Income
-204.1M
↓ 67.26%
Net Profit Margin
-8.17%
↑ 21.74%
Q4 FY22Q/Q Change
Revenue
553.0M
↑ 5.72%
Net Income
-127.7M
↓ 14.13%
Net Profit Margin
-23.1%
↑ 5.34%
Q1 FY23Q/Q Change
Revenue
602.5M
↑ 8.94%
Net Income
-74.2M
↓ 41.95%
Net Profit Margin
-12.31%
↑ 10.79%
Q2 FY23Q/Q Change
Revenue
622.1M
↑ 3.26%
Net Income
-81.0M
↑ 9.27%
Net Profit Margin
-13.02%
↓ 0.71%
Q3 FY23Q/Q Change
Revenue
628.3M
↑ 1.0%
Net Income
794.0K
↓ 100.98%
Net Profit Margin
0.13%
↑ 13.15%
Q4 FY23Q/Q Change
Revenue
646.9M
↑ 2.95%
Net Income
-49.8M
↓ 6367.76%
Net Profit Margin
-7.69%
↓ 7.82%
Q1 FY24Q/Q Change
Revenue
637.5M
↓ 1.45%
Net Income
-110.2M
↑ 121.49%
Net Profit Margin
-17.29%
↓ 9.6%
FY18Y/Y Change
Total Assets
1.5B
↑ 154.61%
Total Liabilities
843.1M
↑ 978.91%
FY19Y/Y Change
Total Assets
3.5B
↑ 130.03%
Total Liabilities
1.2B
↑ 44.44%
FY20Y/Y Change
Total Assets
4.9B
↑ 40.49%
Total Liabilities
2.1B
↑ 72.59%
FY21Y/Y Change
Total Assets
6.7B
↑ 35.73%
Total Liabilities
3.3B
↑ 56.89%
FY22Y/Y Change
Total Assets
6.2B
↓ 6.85%
Total Liabilities
3.2B
↓ 3.44%
FY23Y/Y Change
Total Assets
6.5B
↑ 3.93%
Total Liabilities
3.3B
↑ 4.47%
Q4 FY22Q/Q Change
Total Assets
6.2B
↓ 1.26%
Total Liabilities
3.2B
↓ 0.44%
Q1 FY23Q/Q Change
Total Assets
6.3B
↑ 1.24%
Total Liabilities
3.2B
↑ 1.98%
Q2 FY23Q/Q Change
Total Assets
6.4B
↑ 0.81%
Total Liabilities
3.3B
↑ 1.61%
Q3 FY23Q/Q Change
Total Assets
6.4B
↑ 1.03%
Total Liabilities
3.3B
↑ 0.02%
Q4 FY23Q/Q Change
Total Assets
6.5B
↑ 0.79%
Total Liabilities
3.3B
↑ 0.8%
Q1 FY24Q/Q Change
Total Assets
6.4B
↓ 1.47%
Total Liabilities
3.2B
↓ 2.48%
FY18Y/Y Change
Operating Cash Flow
-69.3M
↓ 3.34%
Investing Cash Flow
-781.9M
↑ 386.25%
Financing Cash Flow
934.1M
↑ 257.97%
FY19Y/Y Change
Operating Cash Flow
-115.0M
↑ 65.9%
Investing Cash Flow
-121.1M
↓ 84.52%
Financing Cash Flow
253.2M
↓ 72.9%
FY20Y/Y Change
Operating Cash Flow
136.5M
↓ 218.67%
Investing Cash Flow
-702.0M
↑ 479.85%
Financing Cash Flow
1.9B
↑ 642.4%
FY21Y/Y Change
Operating Cash Flow
-102.2M
↓ 174.91%
Investing Cash Flow
-1.1B
↑ 54.14%
Financing Cash Flow
8.5M
↓ 99.55%
FY22Y/Y Change
Operating Cash Flow
-223.6M
↑ 118.67%
Investing Cash Flow
74.1M
↓ 106.84%
Financing Cash Flow
76.5M
↑ 802.8%
Q4 FY22Q/Q Change
Operating Cash Flow
52.0M
↓ 227.15%
Investing Cash Flow
-58.2M
↓ 189.47%
Financing Cash Flow
10.1M
↑ 4199.15%
Q1 FY23Q/Q Change
Operating Cash Flow
-38.2M
↓ 173.44%
Investing Cash Flow
82.9M
↓ 242.61%
Financing Cash Flow
133.6M
↑ 1222.34%
Q2 FY23Q/Q Change
Operating Cash Flow
100.4M
↓ 362.79%
Investing Cash Flow
66.5M
↓ 19.85%
Financing Cash Flow
16.0M
↓ 87.99%

Technicals Summary

Sell

Neutral

Buy

Exact Sciences Corporation is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Exact Sciences Corporation
Exact Sciences Corporation
-20.83%
-36.95%
-54.06%
-65.8%
-61.06%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-2.88%
-8.67%
8.38%
-14.56%
89.03%
Agilent Technologies Inc.
Agilent Technologies Inc.
-13.69%
-5.36%
9.36%
-9.57%
86.61%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-3.73%
9.8%
10.1%
21.82%
100.74%
Danaher Corp.
Danaher Corp.
-1.64%
11.24%
6.94%
3.07%
82.63%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-7.43%
-7.2%
0.58%
-12.48%
51.42%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Exact Sciences Corporation
Exact Sciences Corporation
NA
NA
-1.07
-1.13
-0.08
-0.03
NA
17.04
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
49.79
49.79
4.75
11.05
0.72
0.23
NA
18.93
Agilent Technologies Inc.
Agilent Technologies Inc.
30.94
30.94
2.7
5.23
0.21
0.08
0.01
21.31
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
36.9
36.9
2.81
21.72
0.14
0.05
0.0
119.24
Danaher Corp.
Danaher Corp.
48.55
48.55
3.13
7.61
0.08
0.04
0.0
72.16
Iqvia Holdings Inc.
Iqvia Holdings Inc.
29.19
29.19
1.33
11.08
0.22
0.05
NA
34.82
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Exact Sciences Corporation
Exact Sciences Corporation
Buy
$7.9B
-61.06%
NA
-9.48%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$42.5B
89.03%
49.79
23.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$38.1B
86.61%
30.94
18.84%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$219.8B
100.74%
36.9
14.2%
Danaher Corp.
Danaher Corp.
Buy
$198.6B
82.63%
48.55
18.55%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$39.0B
51.42%
29.19
9.01%

Institutional Holdings

  • Vanguard Group Inc

    9.61%
  • Capital World Investors

    7.06%
  • JPMorgan Chase & Co

    6.71%
  • BlackRock Inc

    6.16%
  • Wellington Management Company LLP

    5.79%
  • State Street Corporation

    2.76%

Corporate Announcements

  • Exact Sciences Corporation Earnings

    Exact Sciences Corporation’s price-to-earnings ratio stands at None

    Read More

Company Information

exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences'​ noninvasive colon cancer screening test, visit cologuardtest.com

Organization
Exact Sciences Corporation
Employees
6500
CEO
Mr. Kevin T. Conroy
Industry
Health Technology

FAQs